Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0584 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.6858 |
Open* | 1.6258 |
1-Year Change* | -26.14% |
Day's Range* | 1.6258 - 1.6858 |
52 wk Range | 1.43-2.91 |
Average Volume (10 days) | 14.27K |
Average Volume (3 months) | 395.80K |
Market Cap | 24.38M |
P/E Ratio | -100.00K |
Shares Outstanding | 14.26M |
Revenue | 39.32M |
EPS | -0.17 |
Dividend (Yield %) | N/A |
Beta | 0.15 |
Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 5, 2023 | 1.6458 | 0.0200 | 1.23% | 1.6258 | 1.6858 | 1.6258 |
Dec 4, 2023 | 1.6858 | 0.0000 | 0.00% | 1.6858 | 1.7258 | 1.6858 |
Dec 1, 2023 | 1.6358 | 0.0000 | 0.00% | 1.6358 | 1.6958 | 1.5958 |
Nov 30, 2023 | 1.6358 | -0.0100 | -0.61% | 1.6458 | 1.6758 | 1.6058 |
Nov 29, 2023 | 1.6558 | 0.0000 | 0.00% | 1.6558 | 1.7358 | 1.6158 |
Nov 28, 2023 | 1.7058 | 0.0600 | 3.65% | 1.6458 | 1.7058 | 1.6058 |
Nov 27, 2023 | 1.6458 | -0.0700 | -4.08% | 1.7158 | 1.7558 | 1.6058 |
Nov 24, 2023 | 1.5958 | -0.0400 | -2.45% | 1.6358 | 1.7458 | 1.5958 |
Nov 22, 2023 | 1.6758 | -0.0300 | -1.76% | 1.7058 | 1.7458 | 1.6658 |
Nov 21, 2023 | 1.7058 | 0.0700 | 4.28% | 1.6358 | 1.7558 | 1.6358 |
Nov 20, 2023 | 1.7058 | 0.0300 | 1.79% | 1.6758 | 1.7358 | 1.6058 |
Nov 17, 2023 | 1.6058 | -0.0900 | -5.31% | 1.6958 | 1.8258 | 1.5558 |
Nov 16, 2023 | 1.5458 | -0.1000 | -6.08% | 1.6458 | 1.7258 | 1.5458 |
Nov 15, 2023 | 1.6258 | 0.0300 | 1.88% | 1.5958 | 1.8358 | 1.5858 |
Nov 14, 2023 | 1.6458 | 0.0500 | 3.13% | 1.5958 | 1.7258 | 1.5858 |
Nov 13, 2023 | 1.6058 | -0.0700 | -4.18% | 1.6758 | 1.7558 | 1.5958 |
Nov 10, 2023 | 1.7058 | 0.0300 | 1.79% | 1.6758 | 1.7558 | 1.6158 |
Nov 9, 2023 | 1.5958 | -0.1500 | -8.59% | 1.7458 | 1.8258 | 1.5958 |
Nov 8, 2023 | 1.7758 | -0.2200 | -11.02% | 1.9958 | 1.9958 | 1.7758 |
Nov 7, 2023 | 2.0458 | 0.0800 | 4.07% | 1.9658 | 2.0558 | 1.8958 |
Cumberland Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, March 5, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Cumberland Pharmaceuticals Inc Earnings Release Q4 2023 Cumberland Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, April 24, 2024 | ||
Time (UTC) 14:30 | Country US
| Event Cumberland Pharmaceuticals Inc Annual Shareholders Meeting Cumberland Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 42.0109 | 35.985 | 37.4411 | 34.3883 | 29.3449 |
Revenue | 42.0109 | 35.985 | 37.4411 | 34.3883 | 29.3449 |
Cost of Revenue, Total | 9.11852 | 7.41125 | 8.45302 | 7.42132 | 6.01682 |
Gross Profit | 32.8924 | 28.5738 | 28.9881 | 26.967 | 23.3281 |
Total Operating Expense | 47.7159 | 43.6625 | 43.8227 | 43.6765 | 40.5179 |
Selling/General/Admin. Expenses, Total | 26.5803 | 24.5604 | 24.9618 | 25.2521 | 24.1557 |
Research & Development | 6.68892 | 5.68447 | 5.77383 | 6.86848 | 7.57589 |
Depreciation / Amortization | 5.32811 | 4.60637 | 4.43412 | 4.13456 | 2.76947 |
Operating Income | -5.70493 | -7.67742 | -6.3816 | -9.28818 | -11.173 |
Interest Income (Expense), Net Non-Operating | -0.48759 | -0.07195 | -0.18828 | -0.00283 | 0.36863 |
Net Income Before Taxes | -5.58119 | -5.56223 | -6.56988 | -9.291 | -10.8044 |
Net Income After Taxes | -5.65004 | -5.59712 | -6.62578 | -9.21169 | -10.821 |
Minority Interest | 0.0798 | 0.09521 | 0.0795 | 0.00875 | 0.0757 |
Net Income Before Extra. Items | -5.57024 | -5.50191 | -6.54628 | -9.20294 | -10.7453 |
Net Income | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Income Available to Common Excl. Extra. Items | -5.57024 | -5.50191 | -6.54628 | -9.20294 | -10.7453 |
Income Available to Common Incl. Extra. Items | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Diluted Net Income | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Diluted Weighted Average Shares | 14.5636 | 14.9048 | 15.1622 | 15.3961 | 15.614 |
Diluted EPS Excluding Extraordinary Items | -0.38248 | -0.36914 | -0.43175 | -0.59774 | -0.68818 |
Diluted Normalized EPS | -0.38248 | -0.30808 | -0.42318 | -0.59774 | -0.68818 |
Total Extraordinary Items | 0 | 1.99432 | 3.20688 | 5.66518 | 3.78222 |
Unusual Expense (Income) | 0 | 1.4 | 0.2 | 0 | |
Other, Net | 0.61133 | 2.18714 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 10.8889 | 9.22464 | 9.12368 | 11.4131 | 10.2992 |
Revenue | 10.8889 | 9.22464 | 9.12368 | 11.4131 | 10.2992 |
Cost of Revenue, Total | 1.52077 | 1.25026 | 4.45031 | 1.42444 | 1.63188 |
Gross Profit | 9.36811 | 7.97438 | 4.67337 | 9.98863 | 8.66727 |
Total Operating Expense | 10.866 | 10.7563 | 11.4015 | 11.7017 | 12.1457 |
Selling/General/Admin. Expenses, Total | 7.04196 | 6.77631 | 6.88711 | 6.27652 | 6.76066 |
Research & Development | 1.14504 | 1.49967 | 1.40584 | 1.71425 | 1.82369 |
Depreciation / Amortization | 1.15825 | 1.23007 | 0.45822 | 1.48645 | 1.52945 |
Unusual Expense (Income) | -1.8 | 0.8 | 0.4 | ||
Operating Income | 0.02286 | -1.53168 | -2.2778 | -0.28859 | -1.84654 |
Interest Income (Expense), Net Non-Operating | -0.13558 | -0.13616 | -0.13376 | -0.12774 | -0.12255 |
Net Income Before Taxes | 0.86909 | 0.17922 | -2.41156 | -0.41633 | -1.35777 |
Net Income After Taxes | 0.86215 | 0.17229 | -2.45971 | -0.42323 | -1.36467 |
Minority Interest | 0.01005 | 0.0199 | 0.01899 | 0.01459 | 0.02905 |
Net Income Before Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Total Extraordinary Items | 0 | 0 | 0 | ||
Net Income | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Income Available to Common Excl. Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Income Available to Common Incl. Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Diluted Net Income | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Diluted Weighted Average Shares | 14.5543 | 14.5878 | 14.3974 | 14.4775 | 14.6885 |
Diluted EPS Excluding Extraordinary Items | 0.05993 | 0.01317 | -0.16953 | -0.02823 | -0.09093 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.05993 | 0.01317 | -0.25079 | 0.00769 | -0.07323 |
Other, Net | 0.98181 | 1.84707 | 0 | 0 | 0.61133 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 45.8702 | 45.688 | 49.9696 | 50.1631 | 59.116 |
Cash and Short Term Investments | 19.758 | 27.0408 | 24.7538 | 28.2126 | 36.2296 |
Cash & Equivalents | 19.758 | 27.0408 | 24.7538 | 28.2126 | 27.939 |
Short Term Investments | 0 | 8.29068 | |||
Total Receivables, Net | 13.1637 | 6.87735 | 12.3777 | 9.78146 | 7.84425 |
Accounts Receivable - Trade, Net | 13.1637 | 6.87735 | 12.3777 | 9.78146 | 7.84425 |
Total Inventory | 9.86358 | 8.42988 | 10.6382 | 9.41152 | 12.0783 |
Prepaid Expenses | 3.08498 | 3.33997 | 2.19993 | 2.75746 | 2.96381 |
Total Assets | 92.9252 | 84.4598 | 96.4633 | 104.549 | 112.694 |
Property/Plant/Equipment, Total - Net | 5.50244 | 1.46684 | 2.60232 | 3.70837 | 0.77121 |
Property/Plant/Equipment, Total - Gross | 7.58763 | 5.25899 | 6.1594 | 7.10269 | 3.89592 |
Accumulated Depreciation, Total | -2.08519 | -3.79215 | -3.55709 | -3.39433 | -3.12471 |
Intangibles, Net | 30.5907 | 23.9545 | 28.1183 | 30.9203 | 33.6551 |
Other Long Term Assets, Total | 10.0478 | 12.4685 | 14.8911 | 18.8755 | 18.3675 |
Total Current Liabilities | 28.5798 | 19.279 | 25.6674 | 24.1502 | 27.8042 |
Accounts Payable | 10.819 | 9.64098 | 13.3963 | 11.9124 | 11.0933 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.5374 | 7.30925 | 9.96232 | 9.19241 | 15.0131 |
Total Liabilities | 56.659 | 41.6455 | 49.4728 | 53.4264 | 56.8491 |
Total Long Term Debt | 16.2 | 15 | 15 | 18.5 | 20 |
Long Term Debt | 16.2 | 15 | 15 | 18.5 | 20 |
Minority Interest | -0.29213 | -0.21233 | -0.11712 | -0.03762 | -0.27427 |
Other Liabilities, Total | 12.1713 | 7.57886 | 8.92247 | 10.8138 | 9.31914 |
Total Equity | 36.2661 | 42.8143 | 46.9905 | 51.1229 | 55.8448 |
Common Stock | 47.475 | 48.4529 | 49.1215 | 49.9145 | 51.0986 |
Retained Earnings (Accumulated Deficit) | -11.2088 | -5.6386 | -2.13101 | 1.2084 | 4.74615 |
Total Liabilities & Shareholders’ Equity | 92.9252 | 84.4598 | 96.4633 | 104.549 | 112.694 |
Total Common Shares Outstanding | 14.3663 | 14.7428 | 14.9884 | 15.2636 | 15.4815 |
Goodwill, Net | 0.914 | 0.882 | 0.882 | 0.882 | 0.784 |
Accrued Expenses | 2.22339 | 2.32873 | 2.30884 | 3.04538 | 1.69783 |
Other Current Assets, Total | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 41.7698 | 43.6741 | 43.8108 | 45.8702 | 49.1606 |
Cash and Short Term Investments | 18.508 | 18.2491 | 16.3862 | 19.758 | 19.5415 |
Cash & Equivalents | 18.508 | 18.2491 | 16.3862 | 19.758 | 19.5415 |
Total Receivables, Net | 12.6201 | 12.2188 | 14.5291 | 13.1637 | 15.2327 |
Accounts Receivable - Trade, Net | 12.6201 | 12.2188 | 14.5291 | 13.1637 | 15.2327 |
Total Inventory | 8.67055 | 10.9284 | 10.18 | 9.86358 | 10.6475 |
Prepaid Expenses | 1.97116 | 2.27789 | 2.7155 | 3.08498 | 3.73884 |
Total Assets | 87.7509 | 89.3754 | 89.4686 | 92.9252 | 90.7766 |
Property/Plant/Equipment, Total - Net | 7.08859 | 7.21589 | 5.27391 | 5.50244 | 0.71068 |
Goodwill, Net | 0.914 | 0.914 | 0.914 | 0.914 | 1.93288 |
Intangibles, Net | 27.1211 | 28.2698 | 29.3902 | 30.5907 | 29.048 |
Other Long Term Assets, Total | 10.8575 | 9.30156 | 10.0797 | 10.0478 | 9.92435 |
Total Current Liabilities | 27.3283 | 26.9591 | 25.7074 | 28.5798 | 25.3062 |
Accounts Payable | 10.8181 | 10.912 | 11.2223 | 10.819 | 11.5108 |
Accrued Expenses | 0.33429 | 0.32084 | 0.15837 | 0.17291 | 0.22961 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 16.1759 | 15.7262 | 14.3267 | 17.5879 | 13.5659 |
Total Liabilities | 51.7594 | 52.2164 | 53.1081 | 56.659 | 52.0123 |
Total Long Term Debt | 12.9231 | 13.1481 | 16.0723 | 16.2 | 17.7 |
Long Term Debt | 12.9231 | 13.1481 | 16.0723 | 16.2 | 17.7 |
Minority Interest | -0.33599 | -0.32207 | -0.31202 | -0.29213 | -0.27314 |
Other Liabilities, Total | 11.844 | 12.4312 | 11.6404 | 12.1713 | 9.27921 |
Total Equity | 35.9916 | 37.159 | 36.3605 | 36.2661 | 38.7643 |
Common Stock | 47.1853 | 47.3034 | 47.3772 | 47.475 | 47.5324 |
Retained Earnings (Accumulated Deficit) | -11.1938 | -10.1445 | -11.0167 | -11.2088 | -8.76811 |
Total Liabilities & Shareholders’ Equity | 87.7509 | 89.3754 | 89.4686 | 92.9252 | 90.7766 |
Total Common Shares Outstanding | 14.2179 | 14.331 | 14.43 | 14.3663 | 14.4366 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -5.65004 | -3.6028 | -3.4189 | -3.54651 | -7.03877 |
Cash From Operating Activities | 8.4534 | 6.34244 | 5.41506 | 3.05636 | 3.11274 |
Cash From Operating Activities | 5.32811 | 4.60637 | 4.74857 | 4.40418 | 2.9827 |
Deferred Taxes | 0 | 0 | 0.0218 | 0.06541 | 0.08189 |
Non-Cash Items | -1.66511 | -2.84118 | 0.5308 | 0.70294 | 1.21426 |
Cash Taxes Paid | 0.0033 | -0.00033 | -0.09149 | 0.01669 | 0.01544 |
Cash Interest Paid | 0.52316 | 0.06398 | 0.21599 | 0.19866 | 0.09597 |
Changes in Working Capital | 10.4404 | 8.18005 | 3.5328 | 1.43034 | 5.87267 |
Cash From Investing Activities | -13.6745 | -0.50189 | -1.75779 | 2.29785 | -27.7248 |
Capital Expenditures | -2.07381 | -0.35446 | -2.11393 | -1.01915 | -4.27506 |
Other Investing Cash Flow Items, Total | -11.6006 | -0.14743 | 0.35614 | 3.31699 | -23.4498 |
Cash From Financing Activities | -2.06179 | -3.55353 | -7.11611 | -5.08053 | 7.13817 |
Financing Cash Flow Items | -2.20874 | -2.16668 | -1.76459 | -0.08561 | -0.38331 |
Issuance (Retirement) of Stock, Net | -1.05304 | -1.38685 | -1.85153 | -3.49492 | -2.67852 |
Issuance (Retirement) of Debt, Net | 1.2 | 0 | -3.5 | -1.5 | 10.2 |
Net Change in Cash | -7.28285 | 2.28702 | -3.45884 | 0.27368 | -17.4739 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 0.17229 | -5.65004 | -3.19033 | -2.7671 | -1.40243 |
Cash From Operating Activities | -1.41821 | 8.4534 | 4.81537 | 2.18004 | -0.1505 |
Cash From Operating Activities | 1.25568 | 5.32811 | 4.81663 | 3.27209 | 1.65375 |
Non-Cash Items | -2.05105 | -1.66511 | -0.62674 | 0.05563 | 0.75476 |
Changes in Working Capital | -0.79512 | 10.4404 | 3.8158 | 1.61942 | -1.15657 |
Cash From Investing Activities | -0.17445 | -13.6745 | -13.0337 | -13.7145 | -13.5419 |
Capital Expenditures | -0.17445 | -2.07381 | -0.43304 | -0.21449 | -0.0419 |
Other Investing Cash Flow Items, Total | 0 | -11.6006 | -12.6006 | -13.5 | -13.5 |
Cash From Financing Activities | -1.77914 | -2.06179 | 0.71904 | 2.7102 | 3.91837 |
Financing Cash Flow Items | -1.46431 | -2.20874 | -1.11758 | -0.50151 | -0.50151 |
Issuance (Retirement) of Stock, Net | -0.18712 | -1.05304 | -0.86338 | -0.7883 | -0.58013 |
Issuance (Retirement) of Debt, Net | -0.12771 | 1.2 | 2.7 | 4 | 5 |
Net Change in Cash | -3.3718 | -7.28285 | -7.49928 | -8.82425 | -9.77403 |
Deferred Taxes | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Kazimi (A J) | Individual Investor | 39.7878 | 5717993 | 1093 | 2023-09-29 | LOW |
Renaissance Technologies LLC | Hedge Fund | 3.9018 | 560743 | -10920 | 2023-06-30 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 3.5299 | 507290 | -101743 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6082 | 374826 | 0 | 2023-06-30 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 1.9946 | 286655 | 0 | 2023-06-30 | MED |
Krogulski (Kenneth J) | Individual Investor | 1.5461 | 222193 | 3027 | 2023-10-16 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.3093 | 188164 | 0 | 2023-06-30 | MED |
Cearnal (Martin E) | Individual Investor | 1.1375 | 163473 | -15000 | 2022-03-17 | |
Pavliv (Leo B) | Individual Investor | 0.9367 | 134618 | -33500 | 2022-05-31 | |
Jacobs (Joey A) | Individual Investor | 0.6848 | 98415 | -5000 | 2023-01-14 | LOW |
B. Riley Wealth Advisors, Inc. | Investment Advisor | 0.6283 | 90298 | 90298 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5922 | 85100 | -16987 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.519 | 74583 | 0 | 2023-06-30 | LOW |
Newton Investment Management North America, LLC | Investment Advisor | 0.4999 | 71843 | 71843 | 2023-09-30 | MED |
Galante (Joseph C.) | Individual Investor | 0.4061 | 58356 | 935 | 2023-03-24 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.3954 | 56830 | -300 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2995 | 43045 | 0 | 2023-06-30 | LOW |
Herman (James L.) | Individual Investor | 0.2744 | 39441 | -4280 | 2023-03-18 | LOW |
Jones (James R) | Individual Investor | 0.2027 | 29133 | 1093 | 2023-09-29 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.1989 | 28591 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com